Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

Ascletis completes enrollment in US phase IIa study of small molecule oral GLP-1R agonist, ASC30 to treat obesity: Hong Kong Wednesday, August 6, 2025, 10:00 Hrs [IST] Ascletis Ph ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...

Jefferies upgradeed Gland Pharma to hold, as it believe earnings downcycle for the company is behind and in next 1-2 years can benefit from the generic GLP driven tailwinds ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

Divi's Laboratories, India’s second-largest pharma company by market cap, is expected to report impressive revenue and profit ...

Linda Yaccarino, the former X CEO who left the social media company in the wake of yet another Elon Musk controversy, has ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

The post, at the company that focuses on care for GLP-1 users, comes after Yaccarino left Elon Musk's X in July.

Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, ...

A new drug that skips neurons and targets support cells cut weight and improved insulin response in lab animals, without ...

Former X CEO Linda Yaccarino said Tuesday she has taken on a new role leading a digital health platform, less than a month ...